The distribution agent has begun accepting claims from former Mylan shareholders for a piece of a $30 million settlement fund related to Mylan’s EpiPen emergency epinephrine auto-injectors.

In 2019, Mylan agreed to pay the $30 million penalty to settle Securities and Exchange Commission charges that it failed to timely disclose to investors, among other things, a possible loss relating to a U.S. Department of Justice probe into whether Mylan overcharged Medicaid for EpiPens by misclassifying them as generic.

EpiPens are used to combat life-threatening allergic reactions, such as reactions to foods and insect bites.

The DOJ investigation resulted in a $465 million settlement with Mylan in 2016. The SEC said Mylan failed to disclose the probe to investors before then and didn’t accrue funds to cover any losses.

Advertise with us

The $30 million “Mylan Fair Fund” covers shareholders who purchased Mylan common stock on a U.S. exchange from March 2, 2015, through Sept. 1, 2016, subject to certain eligibility restrictions. Eligibility requirements and other details are available at mylanfairfund.com.

Claim forms and supporting documentation must be submitted online or postmarked on or before March 9, 2022.

Compensation will vary based on dates of the stock transactions, number of shares and the total dollar value of eligible claims, according to RCB Fund Services, the distribution agent.

Claim forms also can be downloaded from the website and mailed to Mylan Fair Fund, P.O. Box 6709, Syracuse, N.Y. 13217-6709. Alternatively, claim forms can be requested by calling 800-678-0888 or by emailing a request to info@mylanfairfund.com.

Mylan merged with Upjohn in November 2020 to form Viatris Inc. The company’s executive offices remain in Cecil.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.